



Alessandro Strusi

Nazionalità: Italiana Data di nascita: 2

ESPERIENZA LAVORATIVA

Medico in Formazione Specialistica in Oncologia Medica

Università Cattolica del Sacro Cuore - Policlinico Universitario "Agostino Gemelli"

[01/01/19 - Attuale]

Città: Roma Paese: Italia

Medico libero professionista presso centro dialisi

Pigreco Omnia Salus SRL [18/03/2019 - 30/10/2019]

Città: Roma Paese: Italia

ISTRUZIONE E FORMAZIONE

Abilitazione Professionale

Ordine Provinciale di Roma dei Medici Chirurghi e degli Odontoiatri [2005-2006]

Città: Roma Paese: Italia

Laurea in Medicina e Chirurgia

Università degli Studi di Roma "La Sapienza" [2012 - 2018]

Città: Roma Paese: Italia Voto finale: 110/110 con lode

Diploma di Scuola Superiore

Liceo Scientifico Statale "Archimede" [2007 - 2012]

Città: Roma Paese: Italia Voto finale: 89/100

COMPETENZE LINGUISTICHE

Lingua madre: italiano

Altre lingue:

inglese

ASCOLTO C1 LETTURA C2 SCRITTURA B2

PRODUZIONE ORALE B2 INTERAZIONE ORALE B2

Livello A1 e A2: Livello elementare B1 e B2: Livello intermedio C1 e C2: Livello avanzato

COMPETENZE DIGITALI

Gestione autonoma della posta e-mail / Padronanza del Pacchetto Office (Word Excel PowerPoint ecc) / Windows

PUBBLICAZIONI

[2024]
The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)-What Future Prospects Are There for Its Use in Clinical Practice? Panebianco M, Ciccarese C, Strusi A, Beccia V, Carbone C, Agostini A, Piro G, Tortora G, Iacovelli R. *The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)-What Future Prospects Are There for Its Use in Clinical Practice?* *Cancers (Basel)*. 2024 Jan 23;16(3):490. doi: 10.3390/cancers16030490. PMID: 38339243.

[2023]
Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario Ciccarese C, Strusi A, Arduini D, Russo P, Palermo G, Foschi N, Racioppi M, Tortora G, Iacovelli R. *Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario*. *Cancer Treat Rev*. 2023 Apr;115:102528. doi: 10.1016/j.ctrv.2023.102528. Epub 2023 Feb 24. PMID: 36905896

[2023]
2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma Anghelone A, Strusi A, Scala A, Panebianco M, Ciccarese C, Iacovelli R. *2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma*. *Expert Rev Anticancer Ther*. 2023 Jul;23(7):669-672. doi: 10.1080/14737140.2023.2218091. Epub 2023 May 29. PMID: 37246571.

[2022]
Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers Iacovelli R, Arduini D, Ciccarese C, Pierconti F, Strusi A, Piro G, Carbone C, Foschi N, Daniele G, Tortora G. *Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers*. *Crit Rev Oncol Hematol*. 2022 Aug;176:103750. doi: 10.1016/j.critrevonc.2022.103750. Epub 2022 Jun 18. PMID: 35728738.

[2022]
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer Stefani A, Piro G, Schietroma F, Strusi A, Vita E, Fiorani S, Barone D, Monaca F, Sparagna I, Valente G, Ferrara MG, D'Argento E, Di Salvatore M, Carbone C, Tortora G, Bria E. *Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer*. *Front Oncol*. 2022 Oct 27;12:1026020. doi: 10.3389/fonc.2022.1026020. PMID: 36387232; PMCID: PMC9647054.

[2024]
Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives Bauckneht M, Ciccarese C, Laudicella R, Mosillo C, D'Amico F, Anghelone A, Strusi A, Beccia V, Bracarda S, Fornarini G, Tortora G, Iacovelli R. *Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives*. *Cancer Treat Rev*. 2024 Mar;124:102698. doi: 10.1016/j.ctrv.2024.102698. Epub 2024 Feb 11. PMID: 38359590.

[2024]
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma, The Tide-A Phase 2 Study Iacovelli R, Ciccarese C, Buti S, Zucali PA, Fantinel E, Bimbatti D, Verzoni E, Accettura C, Bonomi L, Buttigliero C, Fornarini G, Pipitone S, Atzori F, Masini C, Massari F, Primi F, Strusi A, Giudice GC, Perrino M, Maruzzo M, Milella M, Giannarelli D, Brunelli M, Procopio G, Tortora G. *Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study*. *Eur Urol*. 2024 Mar 22;S0302-2838(24)02132-8. doi: 10.1016/j.eururo.2024.02.014. Epub ahead of print. PMID: 38521617.

ATTIVITÀ DI RICERCA

Sub-Investigator

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-Invasive Bladder Cancer (KEYNOTE-866)

Sub-Investigator

A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)

Sub-investigator

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Sub-Investigator

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Sub-investigator

TINivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor

Sub-Investigator

Phase II Study of Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma (Tide-A Study)

Sub-investigator

Open-label, Single-arm, Phase II Study, Evaluating Safety and Efficacy of INCB054828 (Pemigatinib) as Adjuvant Therapy for Molecularly-selected, High-risk Patients With Urothelial Carcinoma Who Have Received Radical Surgery

Sub-investigator

A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (RoAlec)

Sub-investigator

First-line Osimertinib plus Consolidation Radiotherapy compared with Osimertinib alone in oligometastatic NSCLC EGFR mutated patients: the randomized phase II OCRA trial GOIRC-06-2019

Sub-investigator

Phase II, open-label, single-arm, multicenter study to assess the activity and safety of Alectinib as NEO-adjuvant therapy in patients with anaplastic lymphoma kinase-positive (ALK+) locally advanced Stage III Non-Small Cell Lung Cancer (NSCLC).

Autorizzo il trattamento dei miei dati personali presenti nel CV ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n. 196 - "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 - "Regolamento europeo sulla protezione dei dati personali".

ROMA, 17/05/2024